Axel Hauschild

List of Publications by Year
in descending order

76 papers	15,278 citations	101543 36 h-index	69250 77 g-index
81 all docs	81 docs citations	81 times ranked	15562 citing authors

#	Article	IF	Citations
1	Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis. European Journal of Cancer, 2022, 162, 22-33.	2.8	28
2	Real-World Therapy with Pembrolizumab: Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in Germany. Cancers, 2022, 14, 1804.	3.7	4
3	Explainable artificial intelligenceÂin skin cancer recognition: A systematic review. European Journal of Cancer, 2022, 167, 54-69.	2.8	42
4	European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022. European Journal of Cancer, 2022, 170, 256-284.	2.8	92
5	Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline â€“ Update 2022. European Journal of Cancer, 2022, 171, 203-231.	2.8	51
6	Hidden Variables in Deep Learning Digital Pathology and Their Potential to Cause Batch Effects: Prediction Model Study. Journal of Medical Internet Research, 2021, 23, e23436.	4.3	36
7	Robustness of convolutional neural networks in recognition of pigmented skin lesions. European Journal of Cancer, 2021, 145, 81-91.	2.8	32
8	Effectiveness, safety and utilization of vismodegib in locally advanced basal cell carcinoma under realâ€world conditions in Germany â€“ The nonâ€interventional study NIELS. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1678-1685.	2.4	10
9	Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. Lancet Oncology, The, 2021, 22, 848-857.	10.7	150
10	Could controlling occult cytomegalovirus reactivation with prophylactic valganciclovir prevent immune checkpoint blockadeâ€“Related complications?. European Journal of Cancer, 2021, 153, 72-73.	2.8	2
11	Deep learning approach to predict sentinel lymph node status directly from routine histology of primary melanoma tumours. European Journal of Cancer, 2021, 154, 227-234.	2.8	36
12	A benchmark for neural network robustness in skin cancer classification. European Journal of Cancer, 2021, 155, 191-199.	2.8	34
13	Skin cancer classification via convolutional neural networks: systematic review of studies involving human experts. European Journal of Cancer, 2021, 156, 202-216.	2.8	115
14	Integrating Patient Data Into Skin Cancer Classification Using Convolutional Neural Networks: Systematic Review. Journal of Medical Internet Research, 2021, 23, e20708.	4.3	35
15	Rare haematologic and neurologic drug reactions from immune checkpoint inhibition in a responding patient with metastatic anorectal mucosal melanoma. European Journal of Cancer, 2021, , .	2.8	2
16	Response to: Comment on â€˜Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelinesâ€™. European Journal of Cancer, 2020, 140, 154-157.	2.8	1
17	Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma: a joint expert opinion. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 1944-1956.	2.4	94
18	The evolving field of Dermatoâ€oncology and the role of dermatologists: Position Paper of the EADO, EADV and Task Forces, EDF, IDS, EBDVâ€“UEMS and EORTC Cutaneous Lymphoma Task Force. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 2183-2197.	2.4	22

#	Article	IF	Citations
19	Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet, The, 2020, 395, 1558-1568.	13.7	188
20	Efficacy and Safety of Sonidegib in Adult Patients with Nevoid Basal Cell Carcinoma Syndrome (Gorlin Syndrome): Results from a Phase 2, Double-Blind, Randomized Trial . Clinical, Cosmetic and Investigational Dermatology, 2020, Volume 13, 117-121.	1.8	14
21	Comment on â€˜Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelinesâ€™. European Journal of Cancer, 2020, 131, 100-103.	2.8	4
22	Qualityâ€ofâ€life analysis with intermittent vismodegib regimens in patients with multiple basal cell carcinomas: patientâ€reported outcomes from the MIKIE study. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e526-e529.	2.4	4
23	Artificial Intelligence and Its Effect on Dermatologistsâ€™ Accuracy in Dermoscopic Melanoma Image Classification: Web-Based Survey Study. Journal of Medical Internet Research, 2020, 22, e18091.	4.3	45
24	Prediction of melanoma evolution in melanocytic nevi via artificial intelligence: A call for prospective data. European Journal of Cancer, 2019, 119, 30-34.	2.8	33
25	Deep neural networks are superior to dermatologists in melanoma image classification. European Journal of Cancer, 2019, 119, 11-17.	2.8	212
26	Systematic outperformance of 112 dermatologists in multiclass skin cancer image classification by convolutional neural networks. European Journal of Cancer, 2019, 119, 57-65.	2.8	134
27	Diagnosis and treatment of basal cell carcinoma: European consensusâ€“based interdisciplinary guidelines. European Journal of Cancer, 2019, 118, 10-34.	2.8	345
28	A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients. Cancer Immunology, Immunotherapy, 2019, 68, 1547-1559.	4.2	32
29	Superior skin cancer classification by the combination of human and artificial intelligence. European Journal of Cancer, 2019, 120, 114-121.	2.8	197
30	A convolutional neural network trained with dermoscopic images performed on par with 145 dermatologists in a clinical melanoma image classification task. European Journal of Cancer, 2019, 111, 148-154.	2.8	197
31	Reply to E. HindiÃ© and K.R. Hess. Journal of Clinical Oncology, 2019, 37, 1356-1358.	1.6	1
32	Deep learning outperformed 136 of 157 dermatologists in a head-to-head dermoscopic melanoma image classification task. European Journal of Cancer, 2019, 113, 47-54.	2.8	300
33	Adverse events 2.0â€”Let us get SERIOs. European Journal of Cancer, 2019, 112, 29-31.	2.8	19
34	Comparing artificial intelligence algorithms to 157 German dermatologists: the melanoma classification benchmark. European Journal of Cancer, 2019, 111, 30-37.	2.8	104
35	Melanoma. Lancet, The, 2018, 392, 971-984.	13.7	1,016
36	Fear of cancer progression in patients with stage IA malignant melanoma. European Journal of Cancer Care, 2018, 27, e12901.	1.5	19

#	Article	IF	Citations
37	Assessment of quality of life using Skindex-16 in patients with advanced basal cell carcinoma treated with vismodegib in the STEVIE study. European Journal of Dermatology, 2018, 28, 775-783.	0.6	16
38	Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial. Lancet Oncology, The, 2017, 18, 404-412.	10.7	149
39	Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. BMC Cancer, 2017, 17, 332.	2.6	291
40	Adjuvant Dabrafenib plus Trametinib in Stage IIIBRAF-Mutated Melanoma. New England Journal of Medicine, 2017, 377, 1813-1823.	27.0	1,192
41	Immune evasion mechanisms and immune checkpoint inhibition in advanced merkel cell carcinoma. OncoImmunology, 2017, 6, e1338237.	4.6	47
42	Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial. European Journal of Cancer, 2017, 86, 334-348.	2.8	212
43	Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma. Oncologist, 2016, 21, 1218-1229.	3.7	125
44	Photodynamic therapy simplified: nonprepared, moderate-grade actinic keratosis lesions respond equally well to 5-aminolaevulinic acid patch photodynamic therapy as do mild lesions. British Journal of Dermatology, 2015, 173, 1277-1279.	1.5	10
45	A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naÃ¯ve patients with metastatic melanoma. Annals of Oncology, 2015, 26, 2267-2274.	1.2	67
46	Intermittent High-Dose Intravenous Interferon Alfa-2b for Adjuvant Treatment of Stage III Melanoma: Final Analysis of a Randomized Phase III Dermatologic Cooperative Oncology Group Trial. Journal of Clinical Oncology, 2015, 33, 4077-4084.	1.6	29
47	The Impact of Multispectral Digital Skin Lesion Analysis on German Dermatologist Decisions to Biopsy Atypical Pigmented Lesions with Clinical Characteristics of Melanoma. Journal of Clinical and Aesthetic Dermatology, 2015, 8, 27-9.	0.1	5
48	To excise or not: impact of MelaFind on German dermatologistsâ€™ decisions to biopsy atypical lesions. JDDG - Journal of the German Society of Dermatology, 2014, 12, 606-614.	0.8	32
49	Metastatic basal cell carcinoma: Prognosis dependent on anatomic site and spread of disease. European Journal of Cancer, 2014, 50, 774-783.	2.8	154
50	Ipilimumab in patients with cancer and the management of dermatologic adverse events. Journal of the American Academy of Dermatology, 2014, 71, 161-169.	1.2	170
51	Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma. New England Journal of Medicine, 2012, 366, 2171-2179.	27.0	1,201
52	Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet, The, 2012, 380, 358-365.	13.7	2,691
53	Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma. New England Journal of Medicine, 2011, 364, 2517-2526.	27.0	4,074
54	Sorafenib and pegylated interferon-Î±2b in advanced metastatic melanoma: a multicenter phase II DeCOG trial. Annals of Oncology, 2011, 22, 1667-1674.	1.2	27

#	Article	IF	Citations
55	Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion. Annals of Oncology, 2011, 22, 524-535.	1.2	104
56	Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. European Journal of Cancer, 2010, 46, 270-283.	2.8	284
57	Adjuvant Interferon Alfa for Melanoma: New Evidence-Based Treatment Recommendations?. Current Oncology, 2009, 16, 3-6.	2.2	27
58	Optimization of photodynamic therapy with a novel self-adhesive 5-aminolaevulinic acid patch: results of two randomized controlled phase III studies. British Journal of Dermatology, 2009, 160, 1066-1074.	1.5	108
59	Effective photodynamic therapy of actinic keratoses on the head and face with a novel, selfâ€adhesive 5â€aminolaevulinic acid patch. Experimental Dermatology, 2009, 18, 116-121.	2.9	41
60	Phase III, randomized, double-blind study of elesclomol and paclitaxel versus paclitaxel alone in stage IV metastatic melanoma (MM). Journal of Clinical Oncology, 2009, 27, LBA9012-LBA9012.	1.6	2
61	Phase III, randomized, double-blind study of elesclomol and paclitaxel versus paclitaxel alone in stage IV metastatic melanoma (MM). Journal of Clinical Oncology, 2009, 27, LBA9012-LBA9012.	1.6	2
62	Phase III, randomized, double-blind study of elesclomol and paclitaxel versus paclitaxel alone in stage IV metastatic melanoma (MM). Journal of Clinical Oncology, 2009, 27, LBA9012-LBA9012.	1.6	8
63	Practical guidelines for the management of interferonâ€Î±â€2b side effects in patients receiving adjuvant treatment for melanoma. Cancer, 2008, 112, 982-994.	4.1	116
64	New Promises in the Adjuvant, and Palliative Treatment of Melanoma. Cancer Treatment and Research, 2007, 135, 277-292.	0.5	3
65	Randomized phase III study of paclitaxel plus carboplatin with or without sorafenib as second-line treatment in patients with advanced melanoma. Journal of Clinical Oncology, 2007, 25, 8510-8510.	1.6	44
66	Individualized therapy of disseminated cancer using malignant melanoma as a model. Cancer and Metastasis Reviews, 2006, 25, 253-256.	5.9	4
67	A phase II multicenter study on the histone deacetylase (HDAC) inhibitor MS-275, comparing two dosage schedules in metastatic melanoma. Journal of Clinical Oncology, 2006, 24, 8044-8044.	1.6	17
68	Prospective Randomized Trial of Interferon Alfa-2b and Interleukin-2 as Adjuvant Treatment for Resected Intermediate- and High-Risk Primary Melanoma Without Clinically Detectable Node Metastasis. Journal of Clinical Oncology, 2003, 21, 2883-2888.	1.6	68
69	Surgical Standards in the Primary Care of Melanoma Patients. Oncology Research and Treatment, 2003, 26, 218-222.	1.2	16
70	Sentinel node biopsy in melanoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2001, 438, 99-106.	2.8	23
71	Quantification of Melanoma-Associated Molecules in Plasma/Serum of Melanoma Patients. Recent Results in Cancer Research, 2001, 158, 169-177.	1.8	10
72	Predictive value of serum S100B for monitoring patients with metastatic melanoma during chemotherapy and/or immunotherapy. British Journal of Dermatology, 1999, 140, 1065-1071.	1.5	105

#	Article	IF	Citations
73	Prognostic significance of serum S100B detection compared with routine blood parameters in advanced metastatic melanoma patients. Melanoma Research, 1999, 9, 155-162.	1.2	107
74	Multiple painful leiomyomas of the skin: a novel therapy with sympathicolysis?. Journal of the European Academy of Dermatology and Venereology, 1997, 9, 262-265.	2.4	1
75	Eruptive vellus hair cysts and steatocystoma multiplex. Variants of one entity?. British Journal of Dermatology, 1996, 134, 365-367.	1.5	37
76	Formalin-resistant leukocyte surface antigens in the diagnosis of cutaneous malignant lymphomas. American Journal of Pathology, 1989, 135, 177-84.	3.8	8